Please use this identifier to cite or link to this item: http://hdl.handle.net/11455/13628
標題: 犬隻B型及T型淋巴瘤與預後因子相關性研究
The immunophenotype and prognosis in dogs with B-cell or T-cell lymphomas
作者: 林巧雲
Lin, Chiao-Yun
關鍵字: dog

lymphoma
prognosis
淋巴瘤
預後因子
出版社: 獸醫學系暨研究所
引用: References Jack EM, John WH. Tumors of the lymphoid and hematopoietic tissues. In: Tumors in domestic animals 3th ed. California. 6: 240, 1990. Jacobs RM, Messick JB, Valli VE. Tumors of the hemolymphatic system. In: Meuten DJ. Tumor in domestic animals 4th ed. Blackwell publishing Co Iowa State Press, 128-133, 2002. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumors. Pathology and genetic of tumors of hematopoietic and lymphoid tissues. IARC. p 351, 2001. MacEwen EG, Young KM. Canine lymphoma and lymphoid leukemias. In: Withrow SJ, MacEwen EG. Small animal clinical oncology 2th ed. W.B. Saunders com-pany, Philadelphia. 451-479, 1996. Messick JB, Calderwood MB. Classification of lymphomas. In: Schalm's Veterinary Hematology, 5th ed. Feldman BF, Zinkl JG, Jain NC. Lippincott William & Wil-kins. Philadelphia. 604-613, 2000. Morrison WB, Jackson W Y. Chemotherapy options for treatments. In: Moirrson WB. Lymphoma in dogs and cats. Teton NewMedia I: 54-56, 2005. Moore PF, Affolter VK, Vernau W. Immunophenotyping in the dog. In: Bonagura JB. Kirk's current veterinary therapy XIII, small animal practice. W.B. Saunders Co., Philadlphia. 505-509, 2000. Teske, E. Canine malignant lymphoma: a review and comparison with human non- Hodkin's lymphoma. In: Canine Cancer, Hill's Pet Nutrition Inc. 13-29, 1999. Owen LN. In: Owen LN. TNM Classification of Tumors in Domestic Animals.. WHO. Geneva. 47, 1980. Solal-Celigny P, Brousse N, Ferme C, Gisselbrecht C, Reyes F, Coiffier B, Lymphomas. In: Frison-Roche. Lymphomes nonHodgkin's Maladie de Hodgkin 3th ed. Paris, 527, 1997. Arespacochaga AG, Schwendenwein I, Weissenbocky H. Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping. J Comp Path 136: 186-192, 2007. Aquino SM, Hamor RE, Valli VE, Kitchell BE, Tunev SS, Bailey KL, Ehrhart EJ. Pro-gression of an orbital T-cell rich B-cell lymphoma to a B-cell lymphoma in a dog. Vet Pathol 37: 465-469, 2000. Backgren AW, Lymphatic leukosis in dogs: an epizootological, clinical and hematologi-cal study. Acta Vet Scand 6: 1-80, 1965. Baskin CR, Couto CG, Wittum TE. Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study. J Am Anim Hosp Assocs 36: 404-409, 2000. Bell R, Cotter SM, Lillquist A, Characterization of glucocorticoid receptors in animal lymphoblastic disease: correlation with response to single agent glucocorticoid treatment. Blood 63: 380-383, 1984. Burnett RC, Vernau WV, Modiano JF, Olver CS, Moore PF, A. C. Avery AC. Diagnosis of canine lymphoid neoplasia using clonal rearrangements of antigen receptor genes. Vet Pathol 40: 32-41, 2003. Calzolar C, Gentilini F, Agnoli C, Zannoni A, Peli A, Cinotti S, Famigli Bergamini P. PCR assessment of minimal residual disease in 8 lymphoma-affected dogs. Vet Res Commun 30: 258-288, 2006. Carter RF, Valli VEO, Lumsden JH. The cytology, histology and prevalence of cell types in canine lymphoma classified according to the national Cancer Institute Working Formulation. Can J Vet Res 50: 154-164, 1986. Carter RF, Harris CK, Withrow SJ, Valli VEO, Susaneck SJ. Chemotherapy of canine lymphomas with histopathological correlations: doxorubicin alone compared to COP as first treatment regimen. J Amer Anim Hosp Assoc 23:587-596, 1987. Carter RF, Valli VE. Advances in the cytologic diagnosis of canine lymphoma. Semin Vet Med Surg 3: 167-175, 1988. Cotter SM, Goldstein MA. Comparison of two protocol for maintenance of remission of dogs with lymphoma. J Am Anim Hosp Assoc 23: 495-499, 1987. Derkson PWV, Langerak AW, Kerkhof E. Comparison of different polymerase chain reaction-based approaches for clonality assessment of immunoglobulin heave-chain gene rearrangements in B-cell neoplasia. Mod Pathol 12: 749-805, 1999. Dobson JM, Blackwood LB, Mc Innes EF, Bostock DE, Nicholls P, Hoather TM, Tom BD. Prognostic variables in canine multicentric lymphosarcoma. J Small Anim Pract 42: 377-384, 2001. Dorn CR, Taylor DON, Hibbard HH. Epizootiologic characteristics of canine and feline leukemia and lymphoma. Amer J Vet Res 28: 993-1001, 1967. Fisher SG, and Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene 23: 6524-6534, 2004. Fournel-Fleury C, Magnol JP, Bricaire P. Cytohistological and immunological classifi-cation of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J Comp Pathol 117: 35-59, 1997. Fournel-Fleury C, Ponce F, Felman P. Canine T-cell lymphoma: a morphological, im-munological, and clinical study of 46 new cases. Vet Pathol 39: 92-109, 2002. Ghernati I, Auger C, Chabanne L, Corbin A, Bonnefont C, Magnol JP, Fournel C, Ri-voire A, Monier JC, Rigal. Characterization of a canine long-term T cell line (DLC 01) established from a dog with Se´zary syndrome and producing retro-viral particles. Leuk 13: 1281-1290, 1999. Ghernati I, Corbin A, Chabanne L, Auger C, Magnol JP, Fournel C, Monier JC, Darlix JL, Rigal D. Canine large granular lymphocyte leukemia and its derived cell line produce infectious retroviral particles. Vet Pathol 37: 310-317, 2000. Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Briere J, Haioun C, Cazale-Hatem D, Bosly A, Xerri L, Tilly H, Berger F, Bouhabdallah R, Diebold J. Prognostic sig-nificance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 92: 76-82, 1998. Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, Kimmel M, Hurvitz AI, Lieberman PH. Lymphomas in dogs: a morphologic, immunologic, and clinical study. Cancer 66:480-490, 1990. Groves FD, Devesa SS, Linet MS, Travis LB. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from1978 through1995. J Natl Cancer Inst 92: 1240-1251, 2000. Hahn KA, Richardson RC, Hahn EA. Diagnostic and prognostic important of chromo-somal aberration identified in 61 dogs with lymphosarcoma. Vet Pathol 31: 528-540, 1994. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Woolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Mueller-Hermeling HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. A revised European-American classification of lymphoid neoplasms: a proposal from the international study group. Blood 84: 1361-1392, 1994. Hayes HM,Tarone RE, Cantor KP, Jessen CR, DM McCurn, RC Richardson. Case-control study of canine malignant lymphoma: positive association with dog owner''s use of 2, 4-dichlorophenoxyacetic acid herbicides. J Natl Cancer Inst 83: 1226-1231, 1991. Hoogeveen-Westerveld M, Hupkes PE, Doekharan D, Dorssers LCJ, van Veer MB, van Belzen N. Rearranged immunoglobulin light chain genes as minimal residual disease markers in intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma. Leukemia 12: 1810-1816, 1998. Hosoya K, Kisseberth WC, Lord LK, Alvarez FJ, Garcia AL, Kosarek CE, London CA, Couto CG. Comparison of COAP and UW-19 protocols for dogs with multicen-tric lymphoma. J Vet Intern Med 21: 1355-1363, 2007. Isaacson PG. The current status of lymphoma classification. A review. Br J Haematol 109: 258-266, 2000. Jaffe ES. Hematopathology: integration of morphologic features and biologic markers for diagnosis. Mod Pathol 12: 109-115, 1999. Jagielski D, Lechowski R, Hoffmann-Jagielska M, Winiarczyk S. A retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). J Vet Med 49: 419-424, 2002. Jarrett WFH, Mackey LJ. Neoplastic diseases of the hematopoietic and lymphoid tissues. Bull Wld Hlth Org 50: 21-34, 1966. Jones M, Cordell JL, Beyers AD, Tse AGD, Mason DY. Detection of T and B cells in many animal species using cross-reactive anti-peptide antibodies. J Immunol 150: 5429-5435, 1993. Keller ET, Immuno-mediated disease as a risk factor for canine lymphoma. Cancer 70: 2234-2237, 1992. Keller ET, McEwen EG, Rosentha EG, Helfand SC, and Fox LE. Evaluation of prog-nostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Int Med 7: 289-295, 1993. Keller RL, Avery AC, Burnett RC, Walton JA, Olver CS. Detection of neoplastic lym-phocytes in peripheral blood of dogs with lymphoma by polymerase chain reac-tion for antigen receptor gene rearrangement. Vet Clin Pathol 33: 145-149, 2004. Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Suefuji H, Suzumiya J, Harada M, Kikuchi M. Non-B non-T neoplasms with lymphoblast morphology further cla-rification and classification. Am Surg Pathol 27: 1366-1374, 2003. Kiupel M, Teske E, Bostock D. Prognostic facter for treated canine malignant lympho-ma. Vet Pathol 36: 292-300, 1999. Lana SE, Jackson TL, Burnett RC, Morley PS, Avery AC. Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphomas. J Vet Intern Med 20: 329-334, 2006. Landgren O, MacDonald AP, Tani E, Czader M, Grimfors G, Skoog L, Ost A, Wedelin C, Axdorph U, Svedmyr E, Bjorkholm M. A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classifi-cation of lymphomas. Haematol J 5: 69-76, 2004. Lennert K, Feller CA. Histologie des lymphomes malins non-Hodgkin's selon la classi-fication de Kiel classification. Paris, Doin, 1991. MacEwen EG, Brown NO, Patnaik AK. Cyclic combination chemotherapy of canine lmphosarcoma. J Vet Med Assoc 178: 1178-1181, 1981. Mayr B, Holzheu M, Schaffner G, Reifinger M. N-ras mutation in a canine lymphoma: short communication. Acta Vet Hung 51: 91-94, 2003. Mitterbauer-Hohendanner G, Mannhalter C, Winkler K. Prognostic significance of mo-lecular staging by PCR- amplication of immunoglobulin gene rearrangement in diffuse large B-cell lymphoma (DLBCL). Leukemia 18: 1102-1107, 2004. Morley A. Quantifying leukemia. N Engl J Med 339: 627-629, 1998. Moore AS, London CA. Lomustine (CCNU) for the treatment of relapsed lymphoma in dogs. J Vet Internal Med 13: 395-398, 1999. Mutsaers AJ, Glickman NW, DeNicola DB. Evaluation of treatment with doxorubicin and piroxicam or doxorubicin alone for multicentric lymphoma in dogs. J Am Vet Med Assoc 220: 1813-1817, 2002. Ogilvie GK, Moore AS. Managing the veterinary cancer patient: a practice manual. Ve-terinary Learning System 229-249, 1996. Phillips BS, Kass PH, Naydan DK, Winthrop MD, Griffey SM, Madewell BR, Apop-totic and proliferation indexes in canine lymphoma. J Vet Diagn Invest 12: 111-117, 2000. Piiozzi E, Pulford K, Joues M, Muller-Hermelink H, Falini B, Ralfkiaer E, Pileri S, Pezzella F, De Wolf-Peeter C, Arber D, Stein H,Mason D, Gatter K. Co-expression of CD79a (JCB117) and CD3 by lymphoblastic lympjoma. J pa-thol 186: 140-143, 1988. Ponce F, Magnol A J, Blavier A, Bonnefont C, Ghernati I, Felman P, Buff S, Four-nel-Fleury C. Clinical, morphological and immunological study of 13 cases of canine lymphoblastic lymphoma: comparison with the human entity. Comp Clin Pathol 12: 75-83, 2003. Ponce F, Magnol JP, Ledieu D, Marchal T, Turinelli V, Chalvet-Monfray K, Four-nel-Fleury C. Prognostic significance of morphological subtypes in canine ma-lignant lymphomas during chemotherapy. Vet J 167: 158-166, 2004. Postorino NC, Susaneck SJ, Withrow SJ. Single agent therapy with Adriamycin for ca-nine lymphosarcoma. J Am Anim Hosp Assoc 25:221-225, 1989. Price GS, Page RL, Fischer BM, Leving JF, Gerig TM. Efficacy and toxicity of doxoru-bicin/ cyclophosphamide maintenance therapy in dogs with multicentric lym-phosarcoma. J Vet Int Med 5: 259-262, 1991. Proietti FA, Carneiro-Proietti ABF, Catalan-Soares BC, Murphy EL. Global epidemiol-ogy of HTLV-I infection and associated diseases. Oncology 24: 6058-6068, 2005. Ritter JH, Wick MR, Adesokan PN, Fitzgibbon JF, Zhu X, Humpjrey PA. Asessment of clonlity in cutaneous lymphoid infiltrates by polymerase chain reaction analysis of immunoglobulin heavy chain gene rearrangement. Am J Clin Pathol 108: 60-68, 1997. Raskin RE, Krehbiel JD. Prevalence of leukemic blood and bone marrow in dogs with malticentric lymphoma. J Am Vet Med Assoc 194: 1427-1429, 1989. Resboll J, Schultz H, Hougaard P, Nissen N, Hou-jensen K. Comparison of the Working Formulation of non-Hodgkin's lymphoma with the Rappaport, Kiel, and Lukes & Collins classifications. Cancer 55: 2442-2458, 1985. Rosenthal RC, Macewen EG. Treatment of lymphoma in dogs. J Am Vet Assoc 196: 774 -781, 1990. Ruslander DA, Gebhard DH, Tompkins MG. Immunophenotypic characterization of canine lymphoproliferative disorders. In Vivo 11: 169-172, 1997. Sauerbrey ML, Mullins MN, Bannink EO, Renate Van Dorp TE, Kaneene JB, Obrado-vich JE. Lumustine and prednisolone as a first-line treatment for dogs with mul-ticentric lymphoma: 17 cases (2004-2005). JAVMA 230: 1866-1869, 2007. Simon D, Moreno SN, Hirschberger J, Moritz A, Kohn B, Neumann S, Jurian K, Scharvogel S, Schewedes C, Reinacher Manfred R, Beyerbach M, Nolte I. Effi-cacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. JAVMA 232: 879-885, 2008. Sozmen M, Tasca S, Carli E, De Lorenzi D, Furlanello T, Caldin M. Use of fine needle aspirates and flow cytometry for the diagnosis, classification, and immunophe-notyping of canine lymphomas. J Vet Diagn Invest 17: 323-329, 2005. Squire RA, Bush M, Melby EC. Clinical and pathologic study of canine lymphoma: clinical stage, cell classification and therapy. J Natl Cancer Inst 51: 565-574, 1973. Szczepan´ ski T, Langerak AW, Willemse MJ, Wolvers-Tettero ILM, van Wering ER, van Dongen JJM. T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia reflect ‘end-stage' recombinations: implications for minimal residual disease monitoring. Leukemia 14: 1208-1214, 2000. Tani EM, Christensson B, Porwit A, Skoog L. Immunocytochemical analysis and cyto-morphologic diagnosis on fine needle aspirates of lymphoproliferative disease. Acta Cytol 32: 209-215, 1988. Tamura K , Yagihara H, Isotani M, Ono K, Washizu T, Bonkobara M. Development of the polymerase chain reaction assay based on the canine genome database for detection of monoclonality in B cell lymphoma. Vet Immunol Immunopathol 110: 163-167, 2006. Teske E, van Heerde E, Putteman GR, Kurzman ID, Moore PF, MacEwen EG. Prognos-tic facters for treatment of malignant lymphoma in dogs. J Amer Ved Med Assoc 205: 1722-1728, 1994. Teske E, Wisman P, Moore PF. Histologic classification and immunophenotyping of ca-nine non-Hodgkin's lymphomas: unexpected high frequency of T cell lympho-mas with B cell morphology. Exp Hematol 22:1179-1187, 1994. Tindle BH. Teaching monograph: malignant lymphomas. Am J Pathol 116: 115-174, 1984. Valli VE, Jacobs RM, Norris A, Couto CG, Morrison WB, McCaw D, Coter S, Ogilvie G, Moore A. The histological classification of 602 cases of feline lymphoproli-ferative disease using the National Cancer Institute working formulation. J Vet Diagn Invest 12: 296-306, 2000. van Belzen T, Hupkes PE, Doekharan1 D, Hoogeveen-Westerveld M, Dorssers LCJ, Veer MB. Detection of minimal disease using rearranged immunoglobulin heavy chain genes from intermediate- and high-grade malignant B cell non-Hodgkin's lymphoma. Leukemia 11: 1742-1752, 1997. Wilkerson MJ, Dolce K, Koopman T, Shuman W, Chun R, Garrett L, Barber L, Avery A. Lineage differentiation of canine lympgoma/leukemias and aberrant expression of CD molecules. Vet Immunol Immunopathol 106: 179-196, 2005. Yagihara H, Tamura K, Isotani M, Ono K, Washizu T, Bonkobara M. Genomic organi-zation of the T-cell receptor γ gene and PCR detection of its clonal rearrange-ment in canine T-cell lymphoma/leukemia. Vet Immunol Immunopathol 115: 375-382, 2007. Young NA, Al-Saleem TI, Ehya H. Utilization of fine-needle aspiration cytology and flow cytometry in the diagnosis and sub-classification of primary and recurrent lymphoma. Cancer Cytopathol 84: 252-261, 1998. Zemann B, Moore AS. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma. J Vet Internal Med 12: 465-470, 1998.
摘要: 中文摘要 淋巴瘤為犬隻最常見隻血液來源腫瘤,依據腫瘤的來源大致可區分為T細胞來源腫瘤與B細胞來源腫瘤(T-cell lymphoma, B-cell lymphoma),其主要侵犯全身淋巴結及肝脾臟器。現今仍不明造成犬隻淋巴瘤的原因。而由於病犬在接受治療後預後有極大的差異,於是許多學者致力於研究有關疾病預後影響因子,目前研究最為廣泛的影響因子為組織學型態及免疫分型。本篇的實驗目的為探討影響犬隻淋巴瘤的預後因子及利用聚合酶連鎖反應增加應用於預後因子及臨床診斷。2004至2008年由中興獸醫教學醫院蒐集35隻淋巴來源惡性腫瘤的病例,包括25個全身型淋巴瘤、4個皮膚型瘤巴瘤、1個結外淋巴瘤、1個疑似腸道淋巴瘤及4白血病的病例。診斷上合併臨床檢查及細胞學組織學的檢驗。腫瘤組織型態依據Working formulation (WF)的分類系統,細胞學型態依據update Kiel classification的系統分類進行分類。而於免疫分型方面實驗上採用聚合酶連鎖反應及免疫組織化學染色來進行區分B、T細胞來源。結果顯示,以WF分類系統intermediated grade比例最高(70%),而免疫分型面,B-cell lymphoma較T-cell lymphoma常見(60%)。在本實驗中聚合酶連鎖反應可以區分出B、T細胞來源且可作為於病犬於化學治療期間的監測工具,病犬在診斷治療後之平均存活時間為177天(14-741天),而沒有接受治療的病犬平均存活時間為19天(15-137天)。由統計學分析可知影響病犬存活時間的主要因子為病犬對於化學療法的反應以及臨床分級。
Abstract Lymphoma is the most common hematological malignancy. It can be classified as T-cell and B-cell lymphomas based on its origin. The etiology remains obscure. The ranges of survival times and the response to chemotherapy vary among individuals. The immunophenotype and morphology subtype of lymphoma was suggested according to previously research. The aim of this study is to classify the phenotype and morphology associated with prognosis in canine lymphomas. 35 cases of canine lymphoid malignances, including 25 multicentric lymphomas, 4 cutaneous lymphomas, 1 sus-pected intestinal lymphoma, 1 extranodual multicentric lymphoma and 4 leukemias, were collected from our hospital during the period from 2004 to 2008l. Diagnosis was confirmed by the combination of clinical, cytological, and histological examinations. Morphological determination was based on the Working formulation (WF) and the up-date Kiel morphologic classification systems. Immunohistochemistry (IHC) and poly-merase chain reaction (PCR) methods were utilized to classify the phenotype of lym-phomas. Among the patient, mixed breed was the most common breed with lymphoma in this study and B-cell subtype (60%) was predominant in multicentric lymphomas. Intermediate grade (70%) was the most frequent type of lymphomas. In this study, PCR method was successfully applied in immunophenotyping and monitoring the efficacy of treatment of dogs with lymphomas or leukemia. Mean overall survival time in treated dogs and untreated dogs with lymphomas were 177 days (ranging from 14 to 741 days) and 19 days (ranging from 15 to 137 days), respectively. No significant relationships were found between sex, age and survival time. According to Cox proportional hazards model method, the response of chemotherapy and clinical stage were the main factors influencing one-year survival time in dogs with malignant lymphomas.
URI: http://hdl.handle.net/11455/13628
其他識別: U0005-2306200822392000
文章連結: http://www.airitilibrary.com/Publication/alDetailedMesh1?DocID=U0005-2306200822392000
Appears in Collections:獸醫學系所

文件中的檔案:

取得全文請前往華藝線上圖書館



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.